Opiant Pharmaceuticals, Inc.

NasdaqCM:OPNT Rapport sur les actions

Capitalisation boursière : US$108.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Opiant Pharmaceuticals Croissance future

Future contrôle des critères 5/6

Opiant Pharmaceuticals devrait augmenter ses bénéfices et ses revenus de 62.6% et de 39.5% par an respectivement, tandis que le BPA devrait croître de croître de 62.9% par an.

Informations clés

62.6%

Taux de croissance des bénéfices

62.9%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices23.9%
Taux de croissance des recettes39.5%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour15 Nov 2022

Mises à jour récentes de la croissance future

Recent updates

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Aug 13
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Aug 08

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 05
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Mar 21
Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 19
Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Nov 17
These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Sep 19

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Aug 07
Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

Jun 09
Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 06
The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Mar 05
News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Jan 27
Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Dec 14

Opiant Pharmaceuticals receives $50M in convertible debt financing

Dec 10

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:OPNT - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202512538-7-32
12/31/2024779-21-172
12/31/202337-23-31-272
12/31/202210-46N/A-163
9/30/202222-33-16-15N/A
6/30/202239-20-10-10N/A
3/31/202246-6-2-2N/A
12/31/202148322N/A
9/30/2021442-2-2N/A
6/30/202137-1-2-2N/A
3/31/202132-3-1-1N/A
12/31/202030-2-2-2N/A
9/30/202027066N/A
6/30/2020391055N/A
3/31/2020391266N/A
12/31/2019411244N/A
9/30/2019381-3-3N/A
6/30/201921-11-3-3N/A
3/31/201918-14-4-4N/A
12/31/201814-21-1-1N/A
9/30/201834-2-3-3N/A
6/30/201829-5-3-3N/A
3/31/201830-3-5-5N/A
12/31/2017283-9-9N/A
10/31/201717255N/A
7/31/201718766N/A
4/30/201715677N/A
1/31/20171891111N/A
10/31/201611300N/A
7/31/201610-8N/A-1N/A
4/30/201610-8N/A0N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: OPNT devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.1% ).

Bénéfices vs marché: OPNT devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: OPNT devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de OPNT ( 39.5% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de OPNT ( 39.5% par an) devrait croître plus rapidement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de OPNT devrait être élevé dans 3 ans


Découvrir les entreprises en croissance